ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 102 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $460,791 | -54.7% | 86,778 | -18.7% | 0.00% | – |
Q2 2023 | $1,017,328 | +47.7% | 106,750 | +70.4% | 0.00% | – |
Q1 2023 | $688,985 | +1253.3% | 62,635 | +1720.8% | 0.00% | – |
Q4 2022 | $50,913 | -30.3% | 3,440 | -10.9% | 0.00% | – |
Q3 2022 | $73,000 | -6.4% | 3,862 | +5.3% | 0.00% | – |
Q2 2022 | $78,000 | -97.1% | 3,666 | -97.4% | 0.00% | -100.0% |
Q1 2022 | $2,672,000 | -9.0% | 138,735 | -2.0% | 0.00% | 0.0% |
Q4 2021 | $2,936,000 | -84.1% | 141,562 | -81.7% | 0.00% | -75.0% |
Q3 2021 | $18,472,000 | -24.6% | 773,214 | -13.9% | 0.00% | -20.0% |
Q2 2021 | $24,505,000 | -3.4% | 897,972 | +2.4% | 0.01% | -16.7% |
Q1 2021 | $25,360,000 | +40.1% | 876,584 | +36.2% | 0.01% | +50.0% |
Q4 2020 | $18,101,000 | +11.0% | 643,456 | +15.7% | 0.00% | -20.0% |
Q3 2020 | $16,301,000 | +2.3% | 556,363 | +5.5% | 0.01% | 0.0% |
Q2 2020 | $15,941,000 | +29.3% | 527,127 | +27.4% | 0.01% | +25.0% |
Q1 2020 | $12,331,000 | – | 413,771 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
Two Seas Capital LP | 164,807 | $875,125 | 0.18% |